Neuroprotective effect of alpha(2) agonist (brimonidine) on adult rat retinal ganglion cells after increased intraocular pressure - PubMed (original) (raw)
Neuroprotective effect of alpha(2) agonist (brimonidine) on adult rat retinal ganglion cells after increased intraocular pressure
F A Ahmed et al. Brain Res. 2001.
Abstract
Brimonidine, a selective alpha(2)-adrenoceptor agonist, has recently been shown to be neuroprotective as it significantly improves survival of retinal ganglion cells (RGCs) after calibrated optic nerve injury in rats. In the present study, we examined the effect of brimonidine (alpha(2)-adrenoceptor agonist) on RGC survival after increased intraocular pressure (IOP) in adult rats. RGCs were prelabeled by bilateral tectal injection of 5% Fluoro-Gold (FG). Two days later, unilaterally IOP was increased 2.2-2.5 times (28-30.5 mmHg) that of the normal pressure (12.5-14.5 mmHg) by cauterization of three episcleral veins. The elevated IOP was maintained throughout the duration of the experiment. Rats were treated intraperitoneally with brimonidine (1 mg/kg) or phosphate-buffered saline (PBS) once per week beginning either before (group A) or after (group B) increasing the IOP. Another group of rats was left as the control with elevated IOP but without any brimonidine/PBS treatment. Rats were euthanized at 3, 4 and 5 weeks after IOP elevation. Identifiable RGCs were counted and compared between control and experimental groups. Brimonidine significantly protected RGCs from elevated IOP-induced cell death. In control rats with three-vein cauterization, there was 5-6% cell death per week. Almost all RGCs were protected following brimonidine treatment for 3 weeks both in groups A and B. At 4 weeks, there was 4.5% cell death in group A and 6.5% in group B. At 5 weeks, cell death was 5.9% in group A and 6.2% in group B. The difference in cell death in groups A and B was insignificant. No significant differences were observed between PBS-treated and control groups. No significant changes in elevated IOP was found after brimonidine or PBS treatment when compared with the nontreated control group. Although pressure remained elevated throughout the length of the experiment, 3 weeks later the amount of cell death gradually increased in brimonidine-treated animals.
Similar articles
- Retinal ganglion cell neuroprotection in a rat model of glaucoma following brimonidine, latanoprost or combined treatments.
Hernández M, Urcola JH, Vecino E. Hernández M, et al. Exp Eye Res. 2008 May;86(5):798-806. doi: 10.1016/j.exer.2008.02.008. Epub 2008 Mar 4. Exp Eye Res. 2008. PMID: 18394603 - Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension.
WoldeMussie E, Ruiz G, Wijono M, Wheeler LA. WoldeMussie E, et al. Invest Ophthalmol Vis Sci. 2001 Nov;42(12):2849-55. Invest Ophthalmol Vis Sci. 2001. PMID: 11687528 - Alpha-2 adrenergic receptor agonists are neuroprotective in experimental models of glaucoma.
Wheeler LA, Woldemussie E. Wheeler LA, et al. Eur J Ophthalmol. 2001 Jul-Sep;11 Suppl 2:S30-5. doi: 10.1177/112067210101102s03. Eur J Ophthalmol. 2001. PMID: 11592528 - Preclinical evaluation of brimonidine.
Burke J, Schwartz M. Burke J, et al. Surv Ophthalmol. 1996 Nov;41 Suppl 1:S9-18. doi: 10.1016/s0039-6257(96)82027-3. Surv Ophthalmol. 1996. PMID: 8970245 Review. - Review of rodent hypertensive glaucoma models.
Biswas S, Wan KH. Biswas S, et al. Acta Ophthalmol. 2019 May;97(3):e331-e340. doi: 10.1111/aos.13983. Epub 2018 Dec 13. Acta Ophthalmol. 2019. PMID: 30549197 Review.
Cited by
- Effect of brimonidine on vascular density and imagej-derived flow index of optic nerve head and macula in primary open angle glaucoma.
Ameen Ismail A, Sadek S, Hatata R, Kamal M. Ameen Ismail A, et al. Int Ophthalmol. 2024 Jul 4;44(1):311. doi: 10.1007/s10792-024-03221-7. Int Ophthalmol. 2024. PMID: 38963456 - Stable Gastric Pentadecapeptide BPC 157-Possible Novel Therapy of Glaucoma and Other Ocular Conditions.
Sikiric P, Kokot A, Kralj T, Zlatar M, Masnec S, Lazic R, Loncaric K, Oroz K, Sablic M, Boljesic M, Antunovic M, Sikiric S, Strbe S, Stambolija V, Beketic Oreskovic L, Kavelj I, Novosel L, Zubcic S, Krezic I, Skrtic A, Jurjevic I, Boban Blagaic A, Seiwerth S, Staresinic M. Sikiric P, et al. Pharmaceuticals (Basel). 2023 Jul 24;16(7):1052. doi: 10.3390/ph16071052. Pharmaceuticals (Basel). 2023. PMID: 37513963 Free PMC article. Review. - Comparative Analysis of Pupil Diameters in Light and Dark Conditions After Instillation of 0.15% Brimonidine Drops in Eyes With and Without Pseudoexfoliation Syndrome.
Cate S, Bektas C, Turgut B. Cate S, et al. Beyoglu Eye J. 2020 Dec 28;5(3):209-213. doi: 10.14744/bej.2020.52244. eCollection 2020. Beyoglu Eye J. 2020. PMID: 35098090 Free PMC article. - Mechanisms implicated in the contralateral effect in the central nervous system after unilateral injury: focus on the visual system.
Lucas-Ruiz F, Galindo-Romero C, Albaladejo-García V, Vidal-Sanz M, Agudo-Barriuso M. Lucas-Ruiz F, et al. Neural Regen Res. 2021 Nov;16(11):2125-2131. doi: 10.4103/1673-5374.310670. Neural Regen Res. 2021. PMID: 33818483 Free PMC article. Review. - Neuroprotective Strategies for Retinal Ganglion Cell Degeneration: Current Status and Challenges Ahead.
Boia R, Ruzafa N, Aires ID, Pereiro X, Ambrósio AF, Vecino E, Santiago AR. Boia R, et al. Int J Mol Sci. 2020 Mar 25;21(7):2262. doi: 10.3390/ijms21072262. Int J Mol Sci. 2020. PMID: 32218163 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical